# Can Cancer Cell Line In Vitro Radioembolization Model Help to Understand How Beta Radiation Affects Liver Tumor and Improve Treatment Results?

**Authors:** Jerzy Narloch, Aleksandra Majewska, Maciej Maciak, Klaudia Brodaczewska, Piotr Piasecki

PMC · DOI: 10.3390/ijms27041686 · International Journal of Molecular Sciences · 2026-02-09

## TL;DR

This study uses an in vitro model to explore how beta radiation from 90Y-microspheres affects liver tumor and healthy cells under different oxygen conditions.

## Contribution

The study introduces an in vitro model to investigate the effects of beta radiation on cancer and healthy liver cells under normoxic and hypoxic conditions.

## Key findings

- Hypoxia reduces sensitivity to 90Y radiation and promotes a pro-angiogenic tumor environment.
- HCT 116 and THLE-2 cells show radiosensitivity, while HepG2 cells are more resistant to radiation.
- Radiation effects vary by cell type and oxygen levels, influencing apoptosis and angiogenic signaling.

## Abstract

Radioembolization with 90Y-labeled microspheres is an established locoregional therapy for primary and metastatic liver tumors, yet the molecular mechanisms underlying tumor response and resistance, particularly within hypoxic tumor microenvironments, remain poorly understood. Here, we developed an in vitro model of 90Y-microsphere irradiation to investigate the effects of beta radiation under normoxic and hypoxic conditions in human colon cancer (HCT 116), hepatocellular carcinoma (HepG2), and non-malignant liver (THLE2) cell lines. Cells were exposed to two microsphere dilutions, and absorbed doses were estimated using FLUKA-based Monte Carlo simulations. Cellular viability, proliferation, apoptosis-related gene expression, and secretion of angiogenic and inflammatory mediators were assessed. 90Y-microspheres exerted both cytotoxic and cytostatic effects in a cell type- and oxygen-dependent manner. In HCT 116 cells, radiation reduced metabolic activity and proliferation and induced Bax expression in normoxia, whereas hypoxia conferred radioresistance associated with Bcl-2 upregulation. HepG2 cells displayed pronounced resistance, with preserved viability but marked inhibition of proliferation, indicating a predominantly cytostatic response that was further attenuated by hypoxia. In contrast, THLE-2 cells were radiosensitive, showing reduced proliferation and increased Bax expression, while hypoxia partially protected against radiation-induced damage. Both hypoxia and microsphere exposure promoted a pro-angiogenic phenotype, characterized by increased VEGF secretion in radiosensitive tumor and healthy cells, whereas resistant HepG2 cells exhibited angiogenic signaling linked to TIMP2 suppression and IL-8 induction. Collectively, our findings demonstrate that hypoxia diminishes cellular sensitivity to 90Y beta radiation while fostering a microenvironment conducive to tumor progression. This in vitro model provides mechanistic insight into radioembolization responses and may support the development of more personalized therapeutic strategies.

## Linked entities

- **Genes:** BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581], BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596], VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422], TIMP2 (TIMP metallopeptidase inhibitor 2) [NCBI Gene 7077], CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576]
- **Diseases:** colon cancer (MONDO:0002032), hepatocellular carcinoma (MONDO:0007256)

## Full-text entities

- **Genes:** FAS (Fas cell surface death receptor) [NCBI Gene 355] {aka ALPS1A, APO-1, APT1, CD95, FAS1, FASTM}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, TF (transferrin) [NCBI Gene 7018] {aka HEL-S-71p, PRO1557, PRO2086, TFQTL1}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, SERPINE1 (serpin family E member 1) [NCBI Gene 5054] {aka PAI, PAI-1, PAI1, PLANH1}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, HIF3A (hypoxia inducible factor 3 subunit alpha) [NCBI Gene 64344] {aka HIF-3A, HIF3-alpha-1, IPAS, MOP7, PASD7, bHLHe17}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, SPP1 (secreted phosphoprotein 1) [NCBI Gene 6696] {aka BNSP, BSPI, ETA-1, OPN}, PECAM1 (platelet and endothelial cell adhesion molecule 1) [NCBI Gene 5175] {aka CD31, CD31/EndoCAM, GPIIA', PECA1, PECAM-1, endoCAM}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, TIMP2 (TIMP metallopeptidase inhibitor 2) [NCBI Gene 7077] {aka CSC-21K, DDC8}, MIR210 (microRNA 210) [NCBI Gene 406992] {aka MIRN210, mir-210}
- **Diseases:** cytotoxic (MESH:D064420), liver metastases (MESH:D009362), Colon Cancer (MESH:D015179), HCC metastasis (MESH:D006528), Liver Tumor (MESH:D008113), hepatic toxicity (MESH:D056486), -term liver dysfunction (MESH:D017093), cancer (MESH:D009369), injury to (MESH:D014947), liver disease (MESH:D008107), hepatic inflammation (MESH:D007249), pancreatic cancer (MESH:D010190), RILD (MESH:D007953), non-small cell lung cancer (MESH:D002289), Hypoxia (MESH:D000860), Hypoxic (MESH:D002534)
- **Chemicals:** 90Y beta (-), retinoic acid (MESH:D014212), PBS (MESH:D007854), triiodothyronine (MESH:D014284), pO2 (MESH:C093415), Alamar Blue (MESH:C005843), CO2 (MESH:D002245), BrdU (MESH:D001973), EDTA (MESH:D004492), hydrocortisone (MESH:D006854), 90Y (MESH:C000615496), O2 (MESH:D010100), o-phosphorylethanolamine (MESH:C005448)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Mycoplasma (genus) [taxon 2093]
- **Cell lines:** HCT116:2000 — Homo sapiens (Human), Hyperlipoproteinemia, type IIa, Finite cell line (CVCL_1V08), HEPG2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027), Spheres 1 — Mus musculus (Mouse), Hybridoma (CVCL_C7RB), THLE-2 — Homo sapiens (Human), Transformed cell line (CVCL_3803), HCT 116 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_0291)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12941127/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941127/full.md

## References

39 references — full list in the complete paper: https://tomesphere.com/paper/PMC12941127/full.md

---
Source: https://tomesphere.com/paper/PMC12941127